The available report is connected directly to the listing.
Form / material film360° studio loop
Hyperreal material study08.1 sec / seamless
FORM / LOT RECORD
Linked before ordering.
- 01
- Identity
- 02
- Method
- 03
- Lot match
Muscle & Performance
Available for research
Lot-documented reference material
CJC-1295 / Ipamorelin
A two-component peptide reference blend with component-level reporting for clear, confident laboratory review.
Identity + quantity
Reported resultsCurrent lot HVY-5102-CJCIPA · no single blend-purity percentage stated
View lot report →
$90
CoA available
One-time research orderNo subscription
Free U.S. shipping · Freeze-dried · CoA available
Lab-reported identityHPLC & mass spectrometry
Lot matchedCoA available
Freeze-driedReference material
Research onlyQualified buyers
01Material details
Review the identity, current reported result, methods, storage note, and document status in the material table below.
02Independent record
Open the independent report above to verify the values published on this page before placing a research order.
03Research-use requirements
For laboratory research only. Never for use in people or animals. Obtain and review the supplier-issued SDS before handling or storage.
04Potential human benefits
- Recovery + tissue remodelingGrowth hormone and IGF-1 regulate protein synthesis, collagen turnover, and tissue remodeling. Raising those signals creates a plausible pathway for recovery, although the blend has not shown that outcome in controlled human trials.
- Lean-mass potentialThe GH/IGF axis influences muscle protein turnover and fat metabolism. Researchers study whether coordinated secretagogue signaling can improve body composition without supplying growth hormone directly.
- Sleep-linked endocrine supportDeep sleep and pulsatile growth-hormone release are closely connected. Preserving a pulse-like pattern is one reason secretagogues attract interest for sleep and recovery research.
The Form standard
Built to be examined,
not assumed.
Every listing keeps the material, current record, and research boundary in one clear review path.
Review the stated analytical methods before ordering.
Presented as a laboratory reference material.
Research only. Never for use in people or animals.
Potential human relevance
Two complementary signals
for pulsatile GH release.
CJC-1295 extends growth-hormone-releasing-hormone signaling, while ipamorelin activates the ghrelin receptor through a complementary pathway. Small human CJC-1295 studies produced sustained increases in growth hormone and IGF-1; the combined blend is studied for downstream recovery, body-composition, and sleep-related potential.
Recovery + tissue remodeling
Growth hormone and IGF-1 regulate protein synthesis, collagen turnover, and tissue remodeling. Raising those signals creates a plausible pathway for recovery, although the blend has not shown that outcome in controlled human trials.
Lean-mass potential
The GH/IGF axis influences muscle protein turnover and fat metabolism. Researchers study whether coordinated secretagogue signaling can improve body composition without supplying growth hormone directly.
Sleep-linked endocrine support
Deep sleep and pulsatile growth-hormone release are closely connected. Preserving a pulse-like pattern is one reason secretagogues attract interest for sleep and recovery research.
How the potential connects to the biology
Why it may matter
GHRH-receptor and ghrelin/secretagogue-receptor signaling within growth-hormone-axis models.
What studies track
Receptor response, growth-hormone release, IGF-axis markers, and downstream signaling measurements.
How strong is the evidence?
Small human CJC-1295 pharmacodynamic trials; clinical outcome evidence for ipamorelin and the combined blend is limited.
What remains unknown: Human CJC-1295 studies measured GH and IGF-1, not muscle gain, fat loss, sleep, or recovery. No controlled human trial has established benefit for this combined preparation.
Material details
The essentials.
A two-component peptide blend with component identities and lot results shown below.
| Modified GRF (1-29) | CAS 863288-34-0; C152H252N44O42; approximately 3367.9 g/mol |
|---|---|
| Ipamorelin | CAS 170851-70-4; C38H49N9O5; approximately 711.9 g/mol |
| Lot result | Component identity and quantity reported; no single blend-purity percentage is stated on the current CoA |
| Appearance | Lyophilized reference material in sealed vials |
| Tested by | Janoshik Analytical; task #85014; batch HVY-5102-CJCIPA; HPLC and mass spectrometry |
| Storage | Not stated on the current lot CoA. Obtain and follow the supplier-issued SDS before handling or storage. |
| Lab records | Current lot CoA (PDF) · Request supplier-issued SDS |
SDS status: not currently posted. Request and review the supplier SDS before handling or storage; this page and CoA do not replace it.
Made for research
For in-vitro lab research, method development, and identity testing by qualified research customers.
Proof by lot
The available CoA is tied to this material and lot. Open it above or visit the CoA library.
Clear limits
For laboratory research only. Never for use in people or animals.
Before you order
By ordering, you confirm qualified research-only use.
